Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Braltus (tiotropium) 10mcg Inhalation Powder

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Tiotropium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Tiotropium bromide
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What you need to know before you take it

e NEVER place a capsule directly into the Braltus mouthpiece. If you have any problems using Do not use Braltus: the Zonda inhaler, ask your doctor, pharmacist

  • if you are allergic (hypersensitive) to or nurse to show you how it works. tiotropium or any of the other ingredients If necessary, you may wipe the mouthpiece of of this medicine (listed in section 6) your Zonda inhaler after use with a dry cloth
  • if you are allergic (hypersensitive) to atropine or tissue. or substances related to it, e.g. ipratropium Make sure you do not blow into the Zonda or oxitropium
  • if you are allergic (hypersensitive) to lactose inhaler. When using Braltus, take care not to let any of the powder enter your eyes. If any or any other sugars powder does get into your eyes, you may get Warnings and precautions blurred vision, eye pain and/or red eyes; you Talk to your doctor, pharmacist or nurse before should wash your eyes in warm water using Braltus: immediately. Then talk to your doctor
  • if you are taking any other medicinal products immediately for further advice. containing ipratropium or oxitropium If you feel that your breathing is worsening, you
  • if you are suffering from narrow angle should tell your doctor as soon as possible. glaucoma, prostate problems or have difficulty passing urine Use in children and adolescents
  • if you have any kidney problems Braltus should not be used in children and
  • if you have suffered from a heart attack adolescents under the age of 18 years. (myocardial infarction) during the last 6 If you use more Braltus than you should months, or from any unstable or If you inhale the contents of more than 1 life-threatening irregular heart beat or severe capsule of Braltus in a day, you should talk to heart failure in the past year. your doctor immediately. You may be at a Braltus is indicated for maintenance treatment higher risk of experiencing side effects such as of your chronic obstructive pulmonary disease; dry mouth, constipation, difficulties passing it should not be used to treat a sudden attack urine, increased heart beat, or blurred vision. of breathlessness or wheezing. If you forget to use Braltus Immediate allergic reactions such as rash, If you forget to administer a dose, do this as swelling, itching, wheezing or breathlessness soon as you remember, but do not administer may occur after administration of Braltus. If this two doses at the same time or on the same occurs, please consult your doctor day. Then administer your next dose as usual. immediately (see section 4). Do not administer a double dose to make up Inhaled medicines such as Braltus may cause for a forgotten dose. tightness of the chest, coughing, wheezing or If you stop using Braltus breathlessness (bronchospasm) immediately Before you stop using Braltus, you should talk after inhalation. In such instances you should to your doctor or pharmacist. If you stop using immediately use a fast-acting 'reliever' inhaler, this medicine, the signs and symptoms of such as salbutamol. If these symptoms occur COPD may get worse. stop using Braltus inhaler and please consult If you have any further questions on the use of your doctor immediately. this medicine, ask your doctor, pharmacist or Take care not to let the inhalation powder nurse. enter your eyes as this may result in watering 4. Possible side effects eyes or it may cause narrow-angle glaucoma Like all medicines, this medicine can cause side or may worsen this condition. Narrow-angle effects, although not everybody gets them. glaucoma is a disease of the eyes. Eye pain or discomfort, blurred vision, seeing halos around Serious side effects including allergic reactions lights or coloured images in association with which cause swelling of the face or throat red eyes may be signs of an acute attack of (angioedema) or other hypersensitivity reactions narrow-angle glaucoma. Eye symptoms may be (such as sudden reduction of your blood accompanied by headache, nausea or pressure or dizziness) or increased wheezing and vomiting. You should stop using this medicine shortness of breath may occur individually or and immediately consult your doctor, as part of severe allergic reaction (anaphylactic preferably an eye specialist, when signs and reaction) after using this medicine. Such serious symptoms of narrow-angle glaucoma appear. side effects are rare. In addition, in common The medicine in your inhaler may decrease the with all inhaled medicines, some patients may experience unexpected tightness of the chest, normal secretions (saliva) in your mouth and make your mouth feel dry. Long-term this may coughing, wheezing or breathlessness be associated with dental caries (tooth decay). immediately after inhalation (known as bronchospasm). Therefore, please remember to pay attention If any of these side effects occur, please to oral hygiene, rinse your mouth out and consult your doctor immediately. brush your teeth regularly. Do not use your Braltus, inhaler again until you If you have suffered from a heart attack (myocardial infarction) during the last 6 months, have seen or at least spoken with, your doctor. If you are wheezy and short of breath you or from any unstable or life-threatening irregular heart beat or severe heart failure in the should use your fast-acting 'reliever' (rescue) inhaler straightaway. past year, please inform your doctor. This is Other side effects have been experienced by important so that the doctor can decide people using this medicine, and they are listed whether or not Braltus is the right treatment below according to their frequency. for you to use. Common: may affect up to 1 in 10 people Do not use this medicine more than once
  • Dry mouth: this is usually mild daily (see section 3). Uncommon: may affect up to 1 in 100 people Children and adolescents
  • Dizziness Braltus should not be used in children and
  • Headache adolescents under the age of 18 years.
  • Taste disorders

Printed by Andy Lau, 14 Oct 2025 13:51:07 (UTC +01:00)

page 1 of 3 pages

250208_s2 P Tiotropium (BRALTUS) UK Inha Caps 10mcg 30 CHEM_V4.pdf, Cycle:4, Status:Null

  • Blurred vision
  • Irregular heart beat (atrial fibrillation)
  • Sore throat (pharyngitis)
  • Hoarseness (dysphonia)
  • Cough
  • Heart burn (gastrooesophageal reflux disease)
  • Constipation
  • Fungal infections of the mouth and throat (oropharyngeal candidiasis)
  • Rash
  • Difficulty passing urine (urinary retention)
  • Painful urination (dysuria) Rare: may affect up to 1 in 1,000 people
  • Difficulty in sleeping (insomnia)
  • Seeing halos around lights or coloured images in association with red eyes (glaucoma)
  • Increase of the measured eye pressure
  • Irregular heart beat (supraventricular tachycardia)
  • Faster heart beat (tachycardia)
  • Feeling your heart beat (palpitations)
  • Tightness of the chest, associated with coughing, wheezing or breathlessness immediately after inhalation (bronchospasm)
  • Nosebleed (epistaxis)
  • Inflammation of the larynx (laryngitis)
  • Inflammation of the sinuses (sinusitis)
  • Blockage of intestines or absence of bowel movements (intestinal obstruction including ileus paralytic)
  • Inflammation of the gums (gingivitis)
  • Inflammation of the tongue (glossitis)
  • Difficulties swallowing (dysphagia)
  • Inflammation of the mouth (stomatitis)
  • Feeling sick (nausea)
  • Nettle rash (urticaria)
  • Itching (pruritus)
  • Infections of the urinary tract Frequency cannot be estimated from the available data:
  • Depletion of body water (dehydration)
  • Tooth decay (dental caries)
  • Infections or ulcerations of the skin
  • Dryness of the skin
  • Swelling of joints Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible

How to take it

Braltus Braltus contains the active substance tiotropium. Always use this medicine exactly as your doctor Tiotropium helps people who have chronic obstructive pulmonary disease (COPD) to breathe has told you. Check with your doctor or more easily. COPD is a chronic lung disease that pharmacist if you are not sure. causes shortness of breath and coughing. The The recommended dose is to inhale the term COPD is associated with the conditions contents of one capsule once daily with the chronic bronchitis and emphysema. As COPD is Zonda inhaler. One capsule provides the a chronic disease you should use this medicine required daily dose of tiotropium (a delivered every day and not only when you have breathing dose of 10 micrograms of tiotropium); do not problems or other symptoms of COPD. use more than the recommended dose. Braltus is a long-acting bronchodilator that You should try to use this medicine at the same helps to open your airways and makes it easier time every day. This is important because this to get air in and out of the lungs. Regular use medicine is effective over 24 hours. of this medicine can also help you when you The capsules are only for inhalation and not have on-going shortness of breath related to for oral intake. your disease and will help you to minimise the Do not swallow the capsules. effects of the disease on your everyday life. It also helps you to be active longer. Daily use of The Zonda inhaler, which you should put the this medicine will also help to prevent sudden, Braltus capsule into, makes holes in the short-term worsening of your COPD symptoms capsule and allows you to breathe in the powder. The capsules must only be inhaled which may last for several days. The effect of using the Zonda inhaler. Do not use any other this medicine lasts for 24 hours, so you only inhalers to administer Braltus capsules. need to use it once a day. Make sure you know how to use the Zonda This medicine should not be used as a rescue inhaler properly. The instructions for use of the therapy for the treatment of unexpected Zonda inhaler are provided on the other side tightness of the chest, coughing or sudden of this leaflet. Remember to carefully follow attacks of breathlessness or wheezing. Please use a fast-acting 'reliever' (rescue) inhaler, such these instructions for use. Pictures for the correct insertion of the capsule into the as salbutamol instead. Please keep this inhaler are also provided on the inside of the 'reliever' inhaler with you at all times. lid of the carton. To avoid the risk of choking

Possible side effects

not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Braltus Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the bottle label after EXP. The expiry date refers to the last day of that month.

Do not refrigerate or freeze. Keep the bottle tightly closed. Store in the original packaging to protect from moisture. Use the product within 30 days (15 capsule bottle) or 60 days (30 capsule bottle) of opening the bottle. The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack as the inhaler, or in the pack bundled separately with the inhaler pack. Do not reuse the inhaler for another bottle of capsules. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. The inhaler device should be disposed of in accordance with local requirements.

Contents of the pack and other information

What Braltus contains

  • The active substance is tiotropium. Each capsule contains 13 micrograms of the active ingredient tiotropium (as bromide). During inhalation, 10 micrograms of tiotropium are delivered to the patient from each capsule from the mouthpiece of the Zonda inhaler and are inhaled into the lungs.
  • The other ingredients are lactose monohydrate (capsule content) and Hypromellose (capsule shell). What Braltus looks like and contents of the pack Braltus 10 microgram per delivered dose inhalation powder, hard capsule is a colourless and transparent hard capsule, containing white powder. This medicine is provided in bottles, with a screw-cap closure. The bottle is supplied in a carton with a Zonda inhaler. The Zonda Inhaler has a green body and cap with a white push button. Braltus is available in packs containing either 15 or 30 capsules and a Zonda inhaler, and in multipacks containing either 60 capsules (2 packs of 30) and 2 Zonda inhalers or 90 capsules (3 packs of 30) and 3 Zonda inhalers. Bundle pack: 30 capsules (bottle) in a pack bundled with 1 Zonda inhaler packed in a separate pack. Not all pack sizes may be marketed. Marketing Authorisation Holder: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, WF10 5HX, United Kingdom Manufacturer: Laboratorios LICONSA S.A. Avda. Miralcampo, No 7, Polígono Industrial Miralcampo 19200 Azuqueca de Henares, Guadalajara Spain This leaflet was last revised in 09/2025 PL 00289/1870 250208_s2

Zonda Instructions for Use Dear Patient, The Zonda inhaler enables you to inhale the medicine contained in the Braltus capsule that your doctor has prescribed for your breathing problems. Remember to carefully follow your doctor's instructions for using Braltus. The Zonda inhaler is especially designed for Braltus capsules: you must not use it to take any other medication. The capsules must only be inhaled using the Zonda inhaler. Do not use any other inhalers to administer Braltus capsules. Each capsule contains only a small amount of powder. Do not open the capsule or it may not work. The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack, or in the pack bundled separately with the inhaler pack. Do not reuse the inhaler for another bottle of capsules. Discard the Zonda device once the provided capsules use is completed.

Zonda

1. Dust cap 3. Base

5 3

5. Close the mouthpiece until you hear a click, leaving the dust cap open.

2. Mouthpiece

2 1

5

4

4. Piercing button 5. Centre chamber

1

1. Pull the dust cap upwards.

6

2

2. Hold the base of the inhaler firmly and open the mouthpiece by pulling it upwards, in the direction of the arrow.

6. Hold the inhaler with the mouthpiece upwards, and firmly press the piercing button completely in once. Release the button. This will pierce the capsule and allows the medication to be released when you breathe in.

7

7. Breathe out fully. It is important to do this away from the mouthpiece. Avoid breathing into the mouthpiece at any time.

3. Remove a Braltus capsule from the bottle immediately before use and close the bottle tightly. Place one capsule in the centre chamber in the base of the inhaler. Do not store the capsule in the Zonda inhaler.

3

8. Place the mouthpiece in your mouth and keep your head in an upright position. Close your lips around the mouthpiece and breathe in slowly and deeply enough to hear or feel the capsule vibrating inside the centre chamber. Hold your breath for as long as you comfortably can whilst taking the inhaler out of your mouth. Then breathe normally. Repeat steps 7 and 8 to empty the capsule completely.

8

9

4. To avoid the risk of choking NEVER place a capsule directly into the mouthpiece.

9. After use, open the mouthpiece again, and tip out the empty capsule. Close the mouthpiece and dust cap, and store your Zonda inhaler.

The Zonda inhaler is a Medical Device (CE) Manufacturer: Laboratorios LICONSA S.A. Avda. Miralcampo, No 7, Polígono Industrial Miralcampo 19200 Azuqueca de Henares, Guadalajara Spain

4

0051

Printed by Andy Lau, 14 Oct 2025 13:51:07 (UTC +01:00)

250208_s2

page 2 of 3 pages

Frequently asked questions about Braltus (tiotropium) 10mcg Inhalation Powder

How do I take Braltus (tiotropium) 10mcg Inhalation Powder?

Braltus (tiotropium) 10mcg Inhalation Powder comes as inhaler containing 10mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Braltus (tiotropium) 10mcg Inhalation Powder?

The active substance in Braltus (tiotropium) 10mcg Inhalation Powder is tiotropium bromide.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Braltus (tiotropium) 10mcg Inhalation Powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Braltus (tiotropium) 10mcg Inhalation Powder without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Tiotropium bromide (4 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Braltus is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).

Braltus is indicated for use in adults.

4.2. Posology and method of administration

Posology

Route of administration: Inhalation use.

Recommended Dose

Adults 18 years of age and older:

Inhalation of the contents of one capsule once daily with the Zonda inhaler.

Inhalation should be at the same time of day each day.

The recommended dose should not be exceeded.

The delivered dose of a single capsule (10 micrograms) is sufficient and is the standard dose for treatment with Braltus..

Braltus capsules are for inhalation only; they must not be swallowed.

Braltus capsules must only be inhaled with the Zonda inhaler.

Special populations

Elderly patients can use tiotropium bromide at the recommended dose.

Patients with mild renal impairment (creatinine clearance >50 ml/min) can use tiotropium bromide at the recommended dose. For patients with moderate to severe impairment (creatinine clearance ≤50 ml/min) see section 4.4 and section 5.2.

Hepatically impaired patients can use tiotropium bromide at the recommended dose (see section 5.2).

Paediatric population

Braltus should not be used in children or adolescents under 18 years of age. Safety and efficacy have not been established. No data are available.

There is no relevant use for tiotropium bromide in the paediatric population for the indication of COPD.

The safety and efficacy of tiotropium bromide in cystic fibrosis in children and adolescents aged less than 18 years have not been established. No data are available.

Method of administration/Instructions for Use and Handling

To ensure proper administration of the medicinal product, the patient should be trained in the use of the inhaler by either the prescribing physician or by other healthcare professionals.

The Zonda inhaler is especially designed for Braltus capsules; patients must not use it to take any other medication. Braltus capsules must only be inhaled using the Zonda inhaler. Patients must not use any other inhalers to take Braltus capsules. Advise the patient to carefully follow the instructions for use in the patient leaflet. Make the patient aware of the additional pictures on the inside of the lid of the carton which illustrate the correct method for insertion of the capsule into the inhaler. To avoid the risk of choking, instruct the patient to NEVER place a capsule directly into the mouthpiece.

The Zonda inhaler should only be used with the bottle of capsules that will either be provided in the same pack as the inhaler, or in the pack bundled separately with the inhaler pack. Discard the Zonda device once the provided capsules use is completed.

1. Dust cap

2. Mouthpiece

3. Base

4. Piercing button

5. Centre chamber

1. Pull the dust cap upwards.

2. Hold the base of the inhaler firmly and open the mouthpiece by pulling it upwards, in the direction of the arrow to open it.

3. Remove a Braltus capsule from the bottle immediately before use and close the bottle tightly. Place one capsule in the centre chamber in the base of the inhaler. Do not store the capsule in the Zonda inhaler.

4. To avoid the risk of choking, NEVER place a capsule directly into the mouthpiece.

5. Close the mouthpiece until a click is heard, leaving the dust cap open.

6. Hold the inhaler with the mouthpiece upwards, and press the piercing button completely in once. Release the button. This will pierce the capsule and allows the medication to be released when the patient breathes in.

7. Breathe out fully. It is important to do this away from the mouthpiece. Avoid breathing into the mouthpiece at any time.

8. Place the mouthpiece in your mouth and keep your head in an upright position. Close your lips around the mouthpiece and breathe in slowly and deeply enough to hear or feel the capsule vibrating inside the centre chamber.

Hold your breath for as long as you comfortably can whilst taking the inhaler out of your mouth. Then breathe normally. Repeat steps 7 and 8 to empty the capsule completely.

9. After use, open the mouthpiece again, and tip out the empty capsule. Close the mouthpiece and dust cap, and store the Zonda inhaler.

Braltus capsules contain only a small amount of powder, so that the capsule is only partially filled.

If necessary, the patient may wipe the mouthpiece of the Zonda inhaler after use with a dry cloth or tissue.

4.3. Contraindications

Hypersensitivity to the active substance tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium, or to any of the excipients listed in section 6.1, including lactose monohydrate which contains milk protein.

4.4. Special warnings and precautions for use

Tiotropium bromide, as a once daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy.

Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder.

Consistent with its anticholinergic activity, tiotropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. (see section 4.8).

As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Tiotropium should be used with caution in patients with recent myocardial infarction <6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; hospitalisation for heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action.

As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance ≤50 ml/min), tiotropium bromide should be used only if the expected benefit outweighs the potential risk.There is no long term experience in patients with severe renal impairment (see section 5.2).

Patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately.

Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries.

Tiotropium bromide should not be used more frequently than once daily (see section 4.9).

Each capsule contains 18 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.

4.5. Interaction with other medicinal products and other forms of interaction

Although no formal drug interaction studies have been performed, tiotropium bromide inhalation powder has been used concomitantly with other drugs without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, commonly used in the treatment of COPD.

Use of long-acting β2 agonists (LABA) or inhaled corticosteroids (ICS) was not found to alter the exposure to tiotropium.

The co-administration of tiotropium bromide with other anticholinergic drugs has not been studied and is therefore not recommended.

4.6. Fertility, pregnancy and lactation

Fertility

Clinical data on fertility are not available for tiotropium. A non-clinical study performed with tiotropium showed no indication of any adverse effect on fertility (see section 5.3).

Pregnancy

There is a very limited amount of data from the use of tiotropium in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses (see 5.3). As a precautionary measure, it is preferable to avoid the use of Braltus during pregnancy.

Breast-feeding

It is unknown whether tiotropium bromide is excreted in human breast milk. Despite studies in rodents which have demonstrated that excretion of tiotropium bromide in breast milk occurs only in small amounts, use of tiotropium bromide is not recommended during breast-feeding. Tiotropium bromide is a long-acting compound. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Braltus should be made taking into account the benefit of breast-feeding to the child and the benefit of Braltus therapy to the woman.

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. The occurrence of dizziness, blurred vision, or headache may influence the ability to drive and use machinery.

4.8. Undesirable effects

Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium bromide.

The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium) observed in the tiotropium group (9,647 patients) from 28 pooled placebo-controlled clinical trials with treatment periods ranging from four weeks to four years.

Frequency is defined using the following convention:

Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

System Organ Class/MedDRA Preferred Term

Frequency

Metabolism and nutrition disorders

Dehydration

Not known

Nervous system disorders

Dizziness

Headache

Taste disorders

Insomnia

Uncommon

Uncommon

Uncommon

Rare

Eye disorders

Vision blurred

Glaucoma

Intraocular pressure increased

Uncommon

Rare

Rare

Cardiac disorders

Atrial fibrillation

Supraventricular tachycardia

Tachycardia

Palpitations

Uncommon

Rare

Rare

Rare

Respiratory, thoracic and mediastinal disorders

Pharyngitis

Dysphonia

Cough

Bronchospasm

Epistaxis

Laryngitis

Sinusitis

Uncommon

Uncommon

Uncommon

Rare

Rare

Rare

Rare

Gastrointestinal disorders

Dry mouth

Gastro-oesophageal reflux disease

Constipation

Oropharyngeal candidiasis

Intestinal obstruction, including ileus paralytic

Gingivitis

Glossitis

Dysphagia

Stomatitis

Nausea

Dental caries

Common

Uncommon

Uncommon

Uncommon

Rare

Rare

Rare

Rare

Rare

Rare

Not known

Skin and subcutaneous tissue disorders, immune system disorders

Rash

Urticaria

Pruritus

Hypersensitivity (including immediate reactions)

Angioedema

Anaphylactic reaction

Skin infection, skin ulcer

Dry skin

Uncommon

Rare

Rare

Rare

Rare

Not known

Not known

Not known

Musculoskeletal and connective tissue disorders

Joint swelling

Not known

Renal and urinary disorders

Dysuria

Urinary retention

Urinary tract infection

Uncommon

Uncommon

Rare

Allergic reactions

The excipient lactose may contain trace amounts of milk proteins which may cause reactions in those with severe hypersensitivity or allergy to milk protein.

Tiotropium bromide should be discontinued immediately if a hypersensitivity or allergic reaction occurs and the patient should then be managed in the usual way.

Paradoxical bronchospasm

As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Braltus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Description of selected adverse reactions

In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4% of patients.

In 28 clinical trials, dry mouth led to discontinuation in 18 of 9,647 tiotropium treated patients (0.2%).

Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention.

Other special population

An increase in anticholinergic effects may occur with increasing age.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

High doses of tiotropium bromide may lead to anticholinergic signs and symptoms.

However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 microgram tiotropium bromide in healthy volunteers.

Additionally, no relevant adverse effects, beyond dry mouth, were observed following 7 day dosing of up to 170 microgram tiotropium bromide in healthy volunteers. In a multiple dose study in COPD patients with a maximum daily dose of 43 microgram tiotropium bromide over four weeks no significant undesirable effects have been observed.

Acute intoxication by inadvertent oral ingestion of tiotropium bromide capsules is unlikely due to low oral bioavailability.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • SPIRIVA 18 micrograme prescriptionTIOTROPIUM · inhaler / nebuliser
  • GREGAL 10 micrograme prescriptionTIOTROPIUM · inhaler / nebuliser
  • SPIRIVA RESPIMAT 2,5 micrograme prescriptionTIOTROPIUM · inhaler / nebuliser
  • DILOCHOB 18 micrograme prescriptionTIOTROPIUM · inhaler / nebuliser
  • TIOTROPIU VIATRIS 18 micrograme prescriptionTIOTROPIUM · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • SpirivaTiotropium · inhaler / nebuliser
  • Spiriva RespimatTiotropium · inhaler / nebuliser
  • BraltusTiotropium · inhaler / nebuliser
  • SrivassoTiotropium · inhaler / nebuliser
  • AcopairTiotropium · inhaler / nebuliser
  • OntipriaTiotropium · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Braltus (tiotropium) 10mcg Inhalation Powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →